Maddi Hebebrand, MC, Associate Editor

Explore the top headlines of the week including the expanding role of NPs and PAs, a clinician’s guide to chemical peels, and recently announced therapeutic updates.

This week, we feature top articles from our sister publications on women in health care, the relationship between the public and insurance companies, and more.

Geological particles can cause skin irritation, allergies, and long-term dermatological conditions.

A study found that vitiligo patients had a higher incidence of COVID-19 than those with psoriasis or atopic dermatitis.

Researchers investigated whether botulinum toxin enhances fat retention, showing promising clinical results.

This study highlights the urgent need for improved awareness, diagnosis, and treatment of inflammatory nail diseases in patients with skin of color.

The POETYK PSO LTE trial found deucravacitinib effective in sustaining PASI 75 and PASI 90 responses.

A recent study found sunscreen use is higher among women but often not reapplied properly.

Click through our slideshow to see a glimpse of what the 2025 Masterclasses in Dermatology conference has to offer.

Patients treated with dupilumab showed significant reductions in disease severity, itch, and corticosteroid use.

Recent research underscores the critical role of periorbital skin care in maintaining a youthful and healthy appearance across all ethnicities.

Explore the top headlines of the week including the expanding role of NPs and PAs, a clinician’s guide to chemical peels, and recently announced therapeutic updates.

This week, we feature top articles from our sister publications on FDA approvals, top insights, and new data.

A global review found that skin condition advocacy groups offer diverse mental health resources, but accessibility gaps persist worldwide.

Bimekizumab demonstrated long-term effectiveness in patients with HS, with over 85% maintaining response and reduced draining tunnels.

Are you attending Winter Clinical Hawaii? Answer our poll below to let us know.

Hawkes discusses urticaria subtypes, treatments, and emerging therapies like dupilumab and remibrutinib.

Catch up on coverage from the 2025 Masters of Pediatric Dermatology held in Miami Beach, Florida.

New drugs targeting IL-4, IL-13, and IL-31 pathways provide options for tailored eczema treatments.

Catch up on coverage from the 2025 South Beach Symposium held in Miami Beach, Florida.

A recent expert discussion highlighted the importance of long-term planning, including when and how to adjust or transition therapies.

Lio emphasizes that patient comfort and understanding are essential for successful treatment outcomes.

Many patients, especially parents of pediatric patients, exhibit steroid phobia, impacting treatment adherence.

Long-term safety data suggests that JAK inhibitors have a lower risk of cardiovascular and thromboembolic events than previously thought.

Medical and aesthetic dermatologists partner at SBS 2025 to bridge gaps between clinical care and cosmetic procedures.

Catch up on coverage from the third day of the 2025 South Beach Symposium held in Miami Beach, Florida.

Advances in biologics, JAK inhibitors, and PDE4 inhibitors provide personalized options for psoriasis management.

Compliance with acne medications remains a challenge, but timely intervention can prevent severe skin damage.

Many patients with severe AD are unaware of newer, more effective treatments.

A holistic yet time-efficient approach can help dermatologists recognize early joint pain symptoms associated with psoriasis.